Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: An Emerging Therapeutic Strategy

This review synthesizes evidence on disitamab vedotin combined with tislelizumab showing promising efficacy and safety in treating transurethrally unresectable ERBB2-positive very high-risk NMIBC, filling a crucial therapeutic gap for patients ineligible for cystectomy.
Derivation and Validation of Claims-Based Operational Definitions for Cardiogenic Shock: Enhancing Diagnostic Accuracy and Epidemiologic Surveillance

Derivation and Validation of Claims-Based Operational Definitions for Cardiogenic Shock: Enhancing Diagnostic Accuracy and Epidemiologic Surveillance

This review synthesizes evidence on the derivation and validation of a claims-based algorithm for identifying cardiogenic shock (CS), demonstrating its high diagnostic performance and enabling robust large-scale epidemiologic and long-term outcome research.